Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Dicerna Pharmaceuticals Inc (DRNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/09/2021 8-K Quarterly results
Docs: "Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria –"
08/09/2021 8-K Quarterly results
Docs: "Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria –"
05/06/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update – Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 –"
08/11/2020 8-K/A Quarterly results
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress — Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S. — — $312.7 Million in Cash, Cash Equivalents, and Marketable Securities at September 30, 2019; Dicerna to Receive $200.0 Million Upon Close of HBV Agreement with Roche — — Management to Host Conference Call Today at 4:30 p.m. ET — CAMBRIDGE, Mass., - Nov. 7, 2019 - Dicerna™ Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today reported financial results for the thi..."
08/08/2019 8-K Quarterly results
03/30/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Dicerna Reports Third Quarter 2016 Financial and Operational Results"
05/09/2016 8-K Quarterly results
Docs: "Dicerna Reports First Quarter 2016 Financial and Operational Results"
03/10/2016 8-K Form 8-K - Current report
11/10/2015 8-K Quarterly results
Docs: "Dicerna Announces Third Quarter 2015 Financial and Operational Results"
08/06/2015 8-K Quarterly results
Docs: "Dicerna Announces Second Quarter 2015 Financial and Operational Results"
05/11/2015 8-K Quarterly results
Docs: "Dicerna Announces First Quarter 2015 Financial and Operational Results"
03/12/2015 8-K Quarterly results
Docs: "Dicerna Announces Fourth Quarter and Full Year 2014 Financial and Operational Results"
08/07/2014 8-K Quarterly results
Docs: "Dicerna Provides Operational Update and Reports Second Quarter 2014 Financial Results"
03/27/2014 8-K Quarterly results
Docs: "Dicerna Announces Fourth Quarter and Full Year 2013 Financial and Operational Results -DCR-M1711 to Enter Phase 1 Clinical Trials in First Half of 2014- -Management to Host Conference Call at 4:30 PM ET- Watertown, MA, March 27, 2014 - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics, today provided a corporate update and announced operational and financial results for the fourth quarter and full year ended December 31, 2013. “In 2013, Dicerna achieved very substantial financial and operational objectives in our mission to build an innovative drug development company based on the powerful Dicer Substrate RNA interference technology,” commented Douglas M. Fambrough, PhD, Dicerna's President and CEO. “With the completion of our successful initial public ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy